Advances in pharmacotherapies for hyperuricemia

References

• Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, et al. Uric acid and hypertension: an update with recommendations. Am J Hypertens. 2020 Jul 18;33(7):583–594. DOI:10.1093/ajh/hpaa044
   PubMedGoogle Scholar
• Borghi C, Piani F. Uric acid and risk of cardiovascular disease: a question of start and finish. Hypertension. 2021 Nov;78(5):1219–1221.
   PubMedGoogle Scholar
• Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol. 2020 Jan;32(1):71–79.
   PubMed Web of Science ®Google Scholar
• Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323–345.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12(7):3167–3181.
   PubMed Web of Science ®Google Scholar
• Virdis A, Masi S, Casiglia E, et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020 Feb;75(2):302–308. 10.1161/HYPERTENSIONAHA.119.13643.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Kouvari M, Panagiotakos DB, et al. The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study. Rev Cardiovasc Med. 2021 Sep 24;22(3):991–1001. DOI:10.31083/j.rcm2203108
   PubMedGoogle Scholar
• Hisatome I, Li P, Miake J, et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular disease　- Japanese guideline on the management of asymptomatic hyperuricemia. Circ J. 2021 Jan 25;85(2):130–138. DOI:10.1253/circj.CJ-20-0406
   PubMedGoogle Scholar
• MacIsaac RL, Salatzki J, Higgins P, et al. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension. 2016 Mar;67(3):535–540.
   PubMed Web of Science ®Google Scholar
• Gois PHF, Souza ERM. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev. 2017 Apr 13;4(4):Cd008652.
   PubMedGoogle Scholar
• Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008 Jun 17;51(24):2301–2309. DOI:10.1016/j.jacc.2008.01.068
   PubMedGoogle Scholar
• Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for cerebral and cardiorenovascular events PrEvEntion StuDy. Eur Heart J. 2019 Jun 7;40(22):1778–1786. DOI:10.1093/eurheartj/ehz119
   PubMedGoogle Scholar
• Piani F, Cicero AFG, Borghi C. Uric acid and hypertension: prognostic role and guide for treatment. J Clin Med. 2021 Jan 24;10(3):448.
   PubMedGoogle Scholar
• Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018;25(5):545–563. DOI:10.5603/CJ.2018.0116. .
   PubMedGoogle Scholar
• Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008 Jan 3;60(1):59–68.
   PubMedGoogle Scholar
• Kolkhof P, Hartmann E, Freyberger A, et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol. 2021;52(8):642–652. DOI:10.1159/000516213
   PubMed Web of Science ®Google Scholar
• Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004 Mar 16;555(Pt 3):589–606.
   PubMedGoogle Scholar
• Zhao L, Cao L, Zhao TY, et al. Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis. Chin Med J (Engl). 2020 Apr 20;133(8):982–993. DOI:10.1097/CM9.0000000000000682
   PubMedGoogle Scholar
• Liu CW, Chang WC, Lee CC, et al. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2019 Oct;29(10):1011–1022.
   PubMedGoogle Scholar
• Borghi C, Omboni S, Reggiardo G, et al. Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies. BMC Cardiovasc Disord. 2018 Jun 5;18(1):112. DOI:10.1186/s12872-018-0800-x
   PubMedGoogle Scholar
• Bredemeier M, Lopes LM, Eisenreich MA, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018 Feb 7;18(1):24. 10.1186/s12872-018-0757-9.
   PubMedGoogle Scholar
• Zhang S, Xie Q, Xie S, et al. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): a network meta-analysis of randomized trials. Pharmacotherapy. 2021 Sep;41(9):781–791.
   PubMedGoogle Scholar
• Kanbay M, Afsar B, Siriopol D, et al. Effect of uric acid-lowering agents on cardiovascular outcome in patients with heart failure: a systematic review and meta-analysis of clinical studies. Angiology. 2020 Apr;71(4):315–323.
   PubMedGoogle Scholar
• Tsukamoto S, Okami N, Yamada T, et al. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol. 2022 Mar;41(3):911–919. 10.1007/s10067-021-05956-5.
   PubMedGoogle Scholar
• Chewcharat A, Chen Y, Thongprayoon C, et al. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials. Intern Med J. 2021 May;51(5):752–762.
   PubMedGoogle Scholar
• Suzuki S, Yoshihisa A, Yokokawa T, et al. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. J Int Med Res. 2021 Dec;49(12):3000605211062770.
   Google Scholar
• Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol. 2005;147:35–46.
   PubMed Web of Science ®Google Scholar
• Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009 Apr;11(2):135–140.
   PubMedGoogle Scholar
• Kaplow R. Intravenous allopurinol. Clin J Oncol Nurs. 2002 Mar;6(2):110.
   PubMedGoogle Scholar
• Dalbeth N, Bardin T, Doherty M, et al. Discordant American college of physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and crystal-associated disease network (G-CAN). Nat Rev Rheumatol. 2017 Sep;13(9):561–568.
   PubMed Web of Science ®Google Scholar
• Bove M, Cicero AFG, Veronesi M, et al. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. 2017;13:23–28.
   Google Scholar
• Cicero AFG, Fogacci F, Kuwabara M, et al. Therapeutic strategies for the treatment of chronic hyperuricemia: an evidence-based update. Med (Kaunas). 2021 Jan 10;57(1):58. DOI:10.3390/medicina57010058
   PubMedGoogle Scholar
• Hazard A, Bourrion B, Dechaine F, et al. Lack of evidence for allopurinol for the prevention of a first gout attack in asymptomatic hyperuricemia: a systematic review. Eur J Clin Pharmacol. 2020 Jun;76(6):897–899.
   PubMedGoogle Scholar
• Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020 Jun 25;382(26):2504–2513. DOI:10.1056/NEJMoa1915833
   PubMedGoogle Scholar
• Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020 Jun 25;382(26):2493–2503. DOI:10.1056/NEJMoa1916624
   PubMedGoogle Scholar
• Ghane Sharbaf F, Assadi F. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease. Pediatr Nephrol. 2018 Aug;33(8):1405–1409.
   PubMedGoogle Scholar
• Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022 Oct 8;400(10359):1195–1205. DOI:10.1016/S0140-6736(22)01657-9
   PubMedGoogle Scholar
• Deng H, Li Q, Zhu D. Therapeutic effects of allopurinol on the function of left ventricular and activity of matrix metalloproteinase enzymes (MMPs) in patients with chronic heart failure. Cell Mol Biol (Noisy-le-Grand). 2022 May 31;68(5):96–102.
   PubMedGoogle Scholar
• Pascual E, Sivera F, Yasothan U, et al. Febuxostat. Nat Rev Drug Discov. 2009 Mar;8(3):191–192.
   PubMedGoogle Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. DOI:10.1186/ar2978
   PubMed Web of Science ®Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020 Jun;72(6):879–895.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018 Mar 29;378(13):1200–1210. DOI:10.1056/NEJMoa1710895
   PubMedGoogle Scholar
• Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020 Nov 28;396(10264):1745–1757. DOI:10.1016/S0140-6736(20)32234-0
   PubMedGoogle Scholar
• Gao L, Wang B, Pan Y, et al. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis. Clin Cardiol. 2021 Jul;44(7):907–916.
   PubMedGoogle Scholar
• O’dell JR, Brophy MT, Pillinger MH, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. 2022 Mar;1(3). DOI:10.1056/EVIDoa2100028.
   PubMedGoogle Scholar
• Nuki G, Doherty M, Richette P. Current management of gout: practical messages from EULAR 2016 guidelines. Pol Arch Intern Med. 2017 Apr 28;127(4):267–277.
   PubMedGoogle Scholar
• Shekelle PG, Newberry SJ, FitzGerald JD, et al. Management of gout: a systematic review in support of an American college of physicians clinical practice guideline. Ann Intern Med. 2017 Jan 3;166(1):37–51. DOI:10.7326/M16-0461
   PubMedGoogle Scholar
• Tanaka A, Taguchi I, Teragawa H, et al. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial. PLOS Med. 2020 Apr;17(4):e1003095.
   PubMedGoogle Scholar
• Shiina K, Tomiyama H, Tanaka A, et al. Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study. Hypertens Res. 2022 Apr;45(4):602–611.
   PubMedGoogle Scholar
• Kusunose K, Yoshida H, Tanaka A, et al. Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study. Hypertens Res. 2022 Jan;45(1):106–115.
   PubMedGoogle Scholar
• Kohagura K, Kojima S, Uchiyama K, et al. Febuxostat and renal outcomes: post-hoc analysis of a randomized trial. Hypertens Res. 2023 Feb 7. doi: 10.1038/s41440-023-01198-x
   Google Scholar
• Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018 Dec;72(6):798–810.
   PubMed Web of Science ®Google Scholar
• Chen W, Huang N, Mao H, et al. Rationale and design for lowering-hyperUricaemia treatment on cardiovascular outcoMes in peritoNeal diAlysis patients: a prospective, multicentre, double-blind, randomised controlled trial (LUMINA). BMJ Open. 2020 Oct 10;10(10):e037842. DOI:10.1136/bmjopen-2020-037842
   PubMedGoogle Scholar
• Ghang BZ, Lee JS, Choi J, et al. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open. 2022 Jun;8(2):e001944.
   PubMedGoogle Scholar
• Li X, Liu J, Ma L, et al. Pharmacological urate-lowering approaches in chronic kidney disease. Eur J Med Chem. 2019 Mar 15;166:186–196. DOI:10.1016/j.ejmech.2019.01.043.
   PubMedGoogle Scholar
• Lee YH, Song GG. Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: a network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022 Apr;60(4):176–183.
   PubMedGoogle Scholar
• Sakuma M, Toyoda S, Arikawa T, et al. Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: a prospective, randomized, open-label, blinded-end-point clinical trial. PLoS ONE. 2022;17(1):e0261445. DOI:10.1371/journal.pone.0261445
   PubMedGoogle Scholar
• Matsuo H, Ishikawa E, Machida H, et al. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol. 2020 Apr;24(4):307–313.
   PubMedGoogle Scholar
• Yanai H, Adachi H, Hakoshima M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021 Aug 26;22(17):9221. DOI:10.3390/ijms22179221
   PubMedGoogle Scholar
• Jansen TL, Perez-Ruiz F, Tausche AK, et al. International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clin Rheumatol. 2018 Dec;37(12):3159–3165.
   PubMedGoogle Scholar
• Chou HW, Chiu HT, Tsai CW, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2018 Sep 1;33(9):1620–1627. DOI:10.1093/ndt/gfx313
   PubMedGoogle Scholar
• Lai SW, Liao KF, Kuo YH, et al. A head-to-head comparison of benzbromarone and allopurinol on the risk of type 2 diabetes mellitus in people with asymptomatic hyperuricemia. Front Pharmacol. 2021;12:731370.
   PubMedGoogle Scholar
• Lai SW, Liao KF, Kuo YH, et al. Comparison of benzbromarone and allopurinol on primary prevention of the first gout flare in asymptomatic hyperuricemia. J Pers Med. 2022 Apr 27;12(5):697. DOI:10.3390/jpm12050697
   PubMedGoogle Scholar
• Nakata T, Ikeda S, Koga S, et al. Randomized, open-label, cross-over comparison of the effects of benzbromarone and febuxostat on endothelial function in patients with hyperuricemia. Int Heart J. 2020 Sep 29;61(5):984–992. DOI:10.1536/ihj.20-114
   PubMedGoogle Scholar
• Iwata Y, Ito S, Wakabayashi S, et al. TRPV2 channel as a possible drug target for the treatment of heart failure. Lab Invest. 2020 Feb;100(2):207–217.
   PubMedGoogle Scholar
• Robbins N, Gilbert M, Kumar M, et al. Probenecid improves cardiac function in patients with heart failure with reduced ejection fraction in vivo and cardiomyocyte calcium sensitivity in vitro. J Am Heart Assoc. 2018 Jan 13;7(2). DOI:10.1161/JAHA.117.007148
   Google Scholar
• Rubinstein J, Woo JG, Garcia AM, et al. Probenecid improves cardiac function in subjects with a fontan circulation and augments cardiomyocyte calcium homeostasis. Pediatr Cardiol. 2020 Dec;41(8):1675–1688.
   PubMedGoogle Scholar
• Baudoux TE, Pozdzik AA, Arlt VM, et al. Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. Kidney Int. 2012 Nov;82(10):1105–1113.
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Saag KG, Goldfarb DS, et al. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. Rheumatology (Oxford). 2019 Jan 1;58(1):61–69. DOI:10.1093/rheumatology/key245
   PubMedGoogle Scholar
• Shen Z, Gillen M, Miner JN, et al. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Des Devel Ther. 2017;11:2077–2086.
   PubMed Web of Science ®Google Scholar
• Stack AG, Dronamraju N, Parkinson J, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. Am J Kidney Dis. 2021 Apr;77(4):481–489.
   PubMed Web of Science ®Google Scholar
• Poiley J, Steinberg AS, Choi YJ, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 2016 Aug;68(8):2027–2034.
   PubMed Web of Science ®Google Scholar
• Steinberg AS, Vince BD, Choi YJ, et al. The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout. J Rheumatol. 2017 Mar;44(3):374–379.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Takahashi T, Taniguchi T, et al. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021 Aug;22(11):1397–1406.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Sano T, Sasaki T, et al. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):62–70.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Furuno K, Kanda S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):71–79.
   PubMed Web of Science ®Google Scholar
• Agnoletti D, Cicero AFG, Borghi C. The impact of uric acid and hyperuricemia on cardiovascular and renal systems. Cardiol Clin. 2021 Aug;39(3):365–376.
   PubMedGoogle Scholar
• Stack AG, Han D, Goldwater R, et al. Dapagliflozin added to verinurad plus febuxostat further reduces serum uric acid in hyperuricemia: the QUARTZ study. J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2347–2356. DOI:10.1210/clinem/dgaa748
   PubMedGoogle Scholar
• La Grotta R, de Candia P, Olivieri F, et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol Life Sci. 2022 May 3;79(5):273. DOI:10.1007/s00018-022-04289-z
   PubMed Web of Science ®Google Scholar
• Bryant CE, Rajai A, Webb NJA, et al. Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. Pediatr Nephrol. 2021 Oct;36(10):3211–3219.
   PubMedGoogle Scholar
• Derosa G, Maffioli P, Reiner Ž, et al. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016 Jun;76(9):947–956.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015 Dec;102:63–70.
   PubMed Web of Science ®Google Scholar
• Borghi C, Piani F. Uric acid and estimate of renal function. Let’s stick together. Int J Cardiol. 2020 Jul 1;310:157–158. DOI:10.1016/j.ijcard.2020.01.046.
   PubMedGoogle Scholar
• Piani F, Sasai F, Bjornstad P, et al. Hyperuricemia and chronic kidney disease: to treat or not to treat. J Bras Nefrol. 2021 Oct;43(4):572–579.
   PubMedGoogle Scholar
• Piani F, Johnson RJ. Does gouty nephropathy exist, and is it more common than we think? Kidney Int. 2021 Jan;99(1):31–33.
   PubMedGoogle Scholar